A new trading day began on Friday, with Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) stock price up 2.39% from the previous day of trading, before settling in for the closing price of $49.31. CRNX’s price has ranged from $24.10 to $60.25 over the past 52 weeks.
Over the past five-year period, the drop rate of yearbook sales for the company of the Healthcare sector was -12.11%. Meanwhile, its annual earnings per share averaged -35.52%. With a float of $88.18 million, this company’s outstanding shares have now reached $94.55 million.
Crinetics Pharmaceuticals Inc (CRNX) Breakdown of a Key Holders of the stock
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Crinetics Pharmaceuticals Inc is 7.07%, while institutional ownership is 110.05%. The most recent insider transaction that took place on Dec 01 ’25, was worth 225,100. In this transaction Chief Med and Dev Officer of this company sold 5,000 shares at a rate of $45.02, taking the stock ownership to the 66,837 shares. Before that another transaction happened on Dec 01 ’25, when Company’s Officer proposed sale 5,000 for $45.56, making the entire transaction worth $227,800.
Crinetics Pharmaceuticals Inc (CRNX) Recent Fiscal highlights
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -0.88 per share, which was $0.1 higher than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.41 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -35.52% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -2.57% during the next five years compared to -12.11% drop over the previous five years of trading.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Trading Performance Indicators
Here are Crinetics Pharmaceuticals Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 15.12. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3131.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -4.53, a number that is poised to hit -1.34 in the next quarter and is forecasted to reach -5.28 in one year’s time.
Technical Analysis of Crinetics Pharmaceuticals Inc (CRNX)
Compared to the last year’s volume of 1.13 million, its volume of 0.99 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 84.47%.
During the past 100 days, Crinetics Pharmaceuticals Inc’s (CRNX) raw stochastic average was set at 98.05%, which indicates a significant increase from 93.81% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.96 in the past 14 days, which was higher than the 1.78 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $43.82, while its 200-day Moving Average is $34.98. Nevertheless, the first resistance level for the watch stands at $51.45 in the near term. At $52.42, the stock is likely to face the second major resistance level. The third major resistance level sits at $53.85. If the price goes on to break the first support level at $49.05, it is likely to go to the next support level at $47.62. Now, if the price goes above the second support level, the third support stands at $46.65.
Crinetics Pharmaceuticals Inc (NASDAQ: CRNX) Key Stats
With a market capitalization of 4.79 billion, the company has a total of 94,892K Shares Outstanding. Currently, annual sales are 1,040 K while annual income is -298,410 K. The company’s previous quarter sales were 140 K while its latest quarter income was -130,090 K.
